Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL (Cancer Immunology, Immunotherapy, (2021), 70, 12, (3701-3708), 10.1007/s00262-021-03008-0)

Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Watrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL (Cancer Immunology, Immunotherapy, (2021), 70, 12, (3701-3708), 10.1007/s00262-021-03008-0)'. Together they form a unique fingerprint.

Medicine & Life Sciences